Elissa M Abrams1,2, Stephanie C Erdle1,3, Scott B Cameron1, Lianne Soller1,3, Edmond S Chan4,5. 1. Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 2. Division of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, Manitoba, Canada. 3. BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada. 4. Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. echan5@cw.bc.ca. 5. BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada. echan5@cw.bc.ca.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to discuss how to best incorporate oral immunotherapy into your clinical practice based on recent evidence and guidelines, and address controversies. RECENT FINDINGS: Oral immunotherapy is the food immunotherapy treatment with the most literature supporting its use. Recent data from both randomized clinical trials and real-world studies show OIT is especially safe and effective in preschoolers, while avoidance may be less safe than previously thought. OIT guidelines support its use outside of research. Oral immunotherapy can be safely and effectively incorporated into your clinical practice, with careful planning and consideration of scenarios where benefits outweigh risks. Baseline oral food challenges are necessary in clinical trials, but in clinical practice, these are best done when the history is unclear due to resource limitations. There is a role for both regular food and FDA-approved products. Future research should focus on optimizing safety and adherence in the real-world setting.
PURPOSE OF REVIEW: The purpose of this review is to discuss how to best incorporate oral immunotherapy into your clinical practice based on recent evidence and guidelines, and address controversies. RECENT FINDINGS: Oral immunotherapy is the food immunotherapy treatment with the most literature supporting its use. Recent data from both randomized clinical trials and real-world studies show OIT is especially safe and effective in preschoolers, while avoidance may be less safe than previously thought. OIT guidelines support its use outside of research. Oral immunotherapy can be safely and effectively incorporated into your clinical practice, with careful planning and consideration of scenarios where benefits outweigh risks. Baseline oral food challenges are necessary in clinical trials, but in clinical practice, these are best done when the history is unclear due to resource limitations. There is a role for both regular food and FDA-approved products. Future research should focus on optimizing safety and adherence in the real-world setting.
Authors: Lianne Soller; Moshe Ben-Shoshan; Daniel W Harrington; Joseph Fragapane; Lawrence Joseph; Yvan St Pierre; Samuel B Godefroy; Sebastien La Vieille; Susan J Elliott; Ann E Clarke Journal: J Allergy Clin Immunol Date: 2012-08-03 Impact factor: 10.793
Authors: Brian P Vickery; Andrea Vereda; Thomas B Casale; Kirsten Beyer; George du Toit; Jonathan O Hourihane; Stacie M Jones; Wayne G Shreffler; Annette Marcantonio; Rezi Zawadzki; Lawrence Sher; Warner W Carr; Stanley Fineman; Leon Greos; Rima Rachid; M Dolores Ibáñez; Stephen Tilles; Amal H Assa’ad; Caroline Nilsson; Ned Rupp; Michael J Welch; Gordon Sussman; Sharon Chinthrajah; Katharina Blumchen; Ellen Sher; Jonathan M Spergel; Frederick E Leickly; Stefan Zielen; Julie Wang; Georgiana M Sanders; Robert A Wood; Amarjit Cheema; Carsten Bindslev-Jensen; Stephanie Leonard; Rita Kachru; Douglas T Johnston; Frank C Hampel; Edwin H Kim; Aikaterini Anagnostou; Jacqueline A Pongracic; Moshe Ben-Shoshan; Hemant P Sharma; Allan Stillerman; Hugh H Windom; William H Yang; Antonella Muraro; José M Zubeldia; Vibha Sharma; Morna J Dorsey; Hey J Chong; Jason Ohayon; J Andrew Bird; Tara F Carr; Dareen Siri; Montserrat Fernández-Rivas; David K Jeong; David M Fleischer; Jay A Lieberman; Anthony E J Dubois; Marina Tsoumani; Christina E Ciaccio; Jay M Portnoy; Lyndon E Mansfield; Stephen B Fritz; Bruce J Lanser; Jonathan Matz; Hanneke N G Oude Elberink; Pooja Varshney; Stephen G Dilly; Daniel C Adelman; A Wesley Burks Journal: N Engl J Med Date: 2018-11-18 Impact factor: 91.245
Authors: J Andrew Bird; Jonathan M Spergel; Stacie M Jones; Rima Rachid; Amal H Assa'ad; Julie Wang; Stephanie A Leonard; Susan S Laubach; Edwin H Kim; Brian P Vickery; Benjamin P Davis; Jennifer Heimall; Antonella Cianferoni; Andrew J MacGinnitie; Elena Crestani; A Wesley Burks Journal: J Allergy Clin Immunol Pract Date: 2017-10-31
Authors: Brian P Vickery; Jelena P Berglund; Caitlin M Burk; Jason P Fine; Edwin H Kim; Jung In Kim; Corinne A Keet; Michael Kulis; Kelly G Orgel; Rishu Guo; Pamela H Steele; Yamini V Virkud; Ping Ye; Benjamin L Wright; Robert A Wood; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2016-08-10 Impact factor: 10.793
Authors: B M J Flokstra-de Blok; A E J Dubois; B J Vlieg-Boerstra; J N G Oude Elberink; H Raat; A DunnGalvin; J O'B Hourihane; E J Duiverman Journal: Allergy Date: 2009-10-01 Impact factor: 13.146